Users of ecstasy (3,4-methylenedioxymethamphetamine; MDMA) may be at risk of developing MDMA-induced injury to the serotonin (5-HT) system. Previously, there were no methods available for directly evaluating the neurotoxic effects of MDMA in the living human brain. However, development of in vivoneuroimaging tools have begun to provide insights into the effects of ecstasy on the human brain. Single photon emission computed tomography (SPECT), positron emission computed tomography (PET) and proton magnetic resonance spectroscopy (1H-MRS) studies which have evaluated ecstasy's neurotoxic potential will be reviewed and discussed in terms of technical aspects, conceptual issues and future prospects. Although PET and SPECT may be limited by several factors such as the low cortical uptake and the use of a non-optimal reference region (cerebellum) the few studies conducted so far provide suggestive evidence that people who heavily use ecstasy are at risk of developing subcortical, and probably also cortical reductions in serotonin transporter (SERT) densities, a marker of 5-HT neurotoxicity. There seem to be dose-dependent and transient reductions in SERT for which females may be more vulnerable than males. 1H-MRS appears to be a less sensitive technique for studying ecstasy's neurotoxic potential. Whether individuals with a relatively low ecstasy exposure also demonstrate loss of SERT needs to be determined. Because most studies have had a retrospective design, in which evidence is indirect and differs in the degree to which any causal links can be implied, longitudinal studies in human ecstasy users are needed to draw de.nite conclusions.
Battaglia G, Yeh S Y, O'Hearn E, Molliver M E, Kuhar M J, De Souza E B (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther242: 911–916
2.
Boja J W, McNeill R M, Lewin A H, Abraham P, Carroll F I, Kuhar M J (1992) Selective dopamine transporter inhibition by cocaine analogs. Neuroreport3: 984–986
3.
Boja J W, Patel A, Carroll F I, Rahman M A, Philip A, Lewin A H, Kopajtic T A, Kuhar M J (1991) [125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol194: 133–134
4.
Boot B P, Mechan A O, McCann U D, Ricaurte G A (2002) MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol453: 239–244. Retraction in: Ricaurte G A. Euro J Pharmacol (2004) 489: 1.
5.
Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M (2004) A voxel-based PET investigation of the long-term effects of ‘Ecstasy’ consumption on brain serotonin transporters. Am J Psychiatry161: 1181–1199
6.
Cassel J C, Riegert C, Rutz S, Koenig J, Rothmaier K, Cosquer B, Lazarus C, Birthelmer A, Jeltsch H, Jones B C, Jackisch R (2005) Ethanol, 3,4-Methylenedioxymethamphetamine (Ecstasy) and their combination: long-term behavioral, neurochemical and neuropharmacological effects in the rat. Neuropsychopharmacology30: 1870–1882
7.
Chang L, Ernst T, Grob C S, Poland R E (1999) Cerebral 1H-MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users. J Magn Reson Imaging10: 521–526
8.
Choi S R, Hou C, Oya S, Mu M, Kung M P, Siciliano M, Acton P D, Kung H F (2000) Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain. Synapse38: 403–412
9.
Commins D L, Vosmer G, Virus R M, Woolverton W L, Schuster C R, Seiden, L S (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther241: 338–345
10.
Curran H V (2000) Is MDMA (‘Ecstasy’) neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology42: 34–41
11.
Daumann J, Fischermann T, Pilatus U, Thron A, Moeller-Hartmann W, Gouzoulis-Mayfrank E (2004) Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci Lett362: 113–116
12.
Dewar K M, Grondin L, Carli M, Lima L, Reader T A (1992) [3H] paroxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and pchloroamphetamine treatment. J Neurochem58: 250–257
13.
Fantegrossi W E, Woolverton W L, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte G A, Woods J H, Winger G (2004) Behavioral and neurochemical consequences of long-term intravenous selfadministration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology29: 1270–1281
14.
Farde L, Halldin C, Muller L, Suhara T, Karlsson P, Hall H (1994) PET study of [11C] •-CIT binding to monoamine transporters in the monkey and human brain. Synapse16: 93–103
15.
Gamma A, Jerome L, Liechti M E, Sumnall H R (2005) Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Depend77: 185–193
16.
Gijsman H J, Verkes R J, van Gerven J M A, Cohen A F (1999) MDMA study. Neuropsychopharmacology21: 597-597
17.
Guardian (2002) Ecstasy not dangerous, say scientists, By Sarah Baseley, health editor. Monday September 2
18.
Guimaraes A, Schwartz P, Prakash M R, Carr C A, Berger U V, Jenkins B G, Coyle J T, Gonzalez R G (1995) Quantitative in vivo IH nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience69: 1095–1101
19.
Hatzidimitriou G, McCann U D, Ricaurte G A (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci19: 5096–5107
20.
Heinz A, Jones D W (2000) Serotonin transporters in ecstasy users. Br J Psychiatry176: 193–195
21.
Heinz A, Jones D W, Zajicek K, Gorey J G, Juckel G, Higley J D, Weinberger D R (2004) Depletion and restoration of endogenous monoamines affects beta-CIT binding to serotonin but not dopamine transporters in non-human primates. J Neural Transm Suppl68: 29–38
22.
Huang Y, Hwang D R, Narendran R, Sudo Y, Chatterjee R, Bae S A, Mawlawi O, Kegeles L S, Wilson A A, Kung H F, Laruelle M (2002) Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab22: 1377–1398
23.
Insel T R, Battaglia G, Johannessen J N, Marra S, De Souza E B (1989) 3,4-Methylenedioxymethamphetamine (‘ecstasy’) selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther49: 713–720
24.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle D D, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology48: 1517–1521
25.
Kish S J, Furukawa Y, Chang L J, Tong J, Ginovart N, Wilson A, Houle S, Meyer J H (2005) Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?Nucl Med Biol32: 123–128
26.
Kuikka J T, Ahonen A K (1999) Toxic effect of MDMA on brain serotonin neurons. Lancet353: 1269-1269
27.
Kuikka J T, Tiihonen J, Bergstrom K A, Karhu J, Hartikainen P, Viinamaki H, Lansimies E, Lehtonen J, Hakola P (1995) Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med22: 346–350
28.
Laruelle M, Baldwin R M, Malison R T, Zea-Ponce Y, Zoghbi S S, al-Tikriti M S, Sybirska E H, Zimmermann R C, Wisniewski G, Neumeyer J L (1993) SPECT imaging of dopamine and serotonin transporters with [123I] •-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse13: 295–309
29.
Lesch K P, Bengel D, Heils A, Sabol S Z, Greenberg B D, Petri S, Benjamin J, Muller C R, Hamer D H, Murphy D L (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science274: 1527–1531
30.
Lew R, Sabol K E, Chou C, Vosmer G L, Richards J, Seiden L S (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol Exp Ther276: 855–865
31.
Liechti M E, Gamma A, Vollenweider F X (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology154: 161–168
32.
Linnet K, Koed K, Wiborg O, Gregersen N (1995) Serotonin depletion decreases serotonin transporter mRNA levels in rat brain. Brain Res697: 251–253
33.
McCann U D, Ricaurte G A (2001) Caveat emptor: editors beware. Neuropsychopharmacology24: 333–336
34.
McCann U D, Ridenour A, Shaham Y, Ricaurte G A (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’): a controlled study in humans. Neuropsychopharmacology10: 129–138
35.
McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA (‘Ecstasy’) on brain serotonin neurones in human beings. Lancet352: 1433–1437
36.
McCann U D, Szabo Z, Seckin E, Rosenblatt P, Mathews W B, Ravert H T, Dannals R F, Ricaurte G A (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [(11)C]McN5652 and [(11)C]DASB. Neuropsychopharmacology30: 1741–1750
37.
Mas M, Farre M, de la Torre R, Roset P N, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther290: 136–145
38.
Mechan A, Yuan J, Hatzidimitriou G, Irvine R J, McCann U D, Ricaurte G A (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology (in press)
39.
Meyer J S, Ali S F (2002) Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain. Ann N Y Acad Sci965: 373–380
40.
Milak M S, Ogden R T, Vinocur D N, Van Heertum R L, Cooper T B, Mann J J, Parsey R V (2005) Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency. Biol Psychiatry57: 102–106
41.
Molliver M E, Berger U V, Mamounas L A, Molliver D C, O'Hearn E, Wilson, M A (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci600: 649–661
42.
Morley K C, Li K M, Hunt G E, Mallet P E, McGregor I S (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (‘Ecstasy’) in rats. Neuropharmacology46: 954–965
Newberg A B, Amsterdam J D, Wintering N, Ploessl K, Swanson R L, Shults J, Alavi A (2005) 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med46: 973–977
45.
Obergriesser T, Ende G, Braus D F, Henn F A (2001) Hippocampal 1HMRSI in ecstasy users. Eur Arch Psychiatry Clin Neurosci251: 114–116
46.
O'Hearn E, Battaglia G, De Souza E B, Kuhar M J, Molliver M E (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci8: 2788–2803
47.
O'shea E, Granados R, Esteban B, Colado M I, Green A R (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (‘ecstasy’). Neuropharmacology37: 919–926
48.
Parsey R V, Kegeles L S, Hwang D R, Simpson N, Abi-Dargham A, Mawlawi O, Slifstein M, Van Heertum R L, Mann J J, Laruelle M (2000) In vivo quantification of brain serotonin transporters in humans using [11C]McN5652. J Nucl Med41: 1465–1477
49.
Peroutka S J (1987) Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, ‘ecstasy’) on an undergraduate campus. N Engl J Med317: 1542–1543
50.
Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauascher J, Willeit M, Neurmeister A, Praschak-Rieder N, Angelberger P, Brücke T (2000) Imaging serotonin and dopamine transporters with 123I- •-CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med41: 36–44
51.
Ramamoorthy S, Blakely R D (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science285: 763–766
52.
Reneman L, Majoie C B L M, Flick H, den Heeten G J (2002a) Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethaphetamine (‘Ecstasy’) users – preliminary results. AJNR Am J Neuroradiol23: 231–237
53.
Reneman L, Schmand B, Bakker O, Schilt T, de Win M M, van den Brink W (2006) Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmacol (in press)
54.
Reneman L, Booij J, de Bruin K, de Wolff F A, Gunning W B, den Heeten G J, van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet358: 1864–1869
55.
Reneman L, Booij J, Habraken J B A, de Bruin K, Hatzidimitriou G, den Heeten G J, Ricaurte G A (2002b) Validity of [123I] •-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse46: 199–205
56.
Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma J B, Gunning W B, den Heeten G J, van den Brink W (2002c) Use of amphetamine by recreational users of ecstasy is associated with reduced striatal dopamine transporter densities: a [123I] •-CIT SPECT study. Psychopharmacology159: 335–340
57.
Ricaurte G A, McCann U D (2001) Assessing long-term effects of MDMA (Ecstasy). Lancet358: 1831–1832
58.
Ricaurte G A, Yuan J, McCann U D (2000) (+/-)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology42: 5–10
59.
Ricaurte G A, Finnegan K T, Irwin I, Langston J W (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci600: 699–708
60.
Ricaurte G A, DeLanney L E, Wiener S G, Irwin I, Langston J W (1988a) 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res474: 359–363
61.
Ricaurte G A, Forno L S, Wilson M A, DeLanney L E, Irwin I, Molliver M E, Langston J W (1988b) (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA260: 51–55
62.
Ricaurte G A, Yuan J, Hatzidimitriou G, Cord B J, McCann U D (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (‘ecstasy’). Science297: 2260–2263 (retraction Science (2003) 301: 1479-1479)
63.
Roiser J P, Cook L J, Cooper J D, Rubinsztein D C, Sahakian B J (2005) Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry162: 609–612
64.
Scheffel U, Ricaurte G A (1990) Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomograpy ligand?Brain Res527: 89–95
65.
Scheffel U, Dannals R F, Cline E J, Ricaurte G A, Carroll F I, Abraham P, Lewin A H, Kuhar M J (1991) [123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse11: 134–139
66.
Scheffel U, Szabo Z, Mathews W B, Finley P A, Dannals R F, Ravert H T, Szabo K, Yuan J, Ricaurte G A (1998) In vivo detection of short- and long-term MDMA neurotoxicity – a positron emission tomography study in the living baboon brain. Synapse29: 183–192
67.
Schmidt C J, Taylor V L (1987) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol36: 4095–4102
68.
Semple D M, Ebmeier K P, Glabus M F, O'Carroll R E, Johnstone E C (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. Br J Psychiatry175: 63–69
69.
Simmons M L, Frondoza C G, Coyle J T (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience45: 37–45
70.
Slikker W, Ali S F, Scallet A C, Frith C H, Newport G D, Bailey J R (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol94: 448–457
71.
Strauss I, Williamson J M, Bertram E H (1997) Histological and 1H magnetic resonance spectroscopic imaging analysis of quinolinic acidinduced damage to the rat striatum. Magn Res Med37: 24–33
72.
Szabo Z, McCann U D, Wilson A A, Scheffel U, Owonikoko T, Mathews W B, Ravert H T, Hilton J, Dannals R F, Ricaurte G A (2002) Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med43: 678–692
73.
Swaab D F, Fliers E (1985) A sexually dimorphic nucleus in the human brain. Science228: 1112–1115
74.
Time Magazine (2000) Ecstasy, what does it do to your brain? June 5 155 (23)
75.
Urenjak J, Williams S R, Gadian D G, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci13: 981–989
76.
Verkes R J, Gijsman H J, Pieters M S, Schoemaker R C, de Visser S, Kuijpers M, Pennings E J, de Bruin D, Van de Wijngaart G, Van Gerven J M, Cohen A F (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology153: 196–202
77.
de Win M M L, Habraken J B A, Reneman L, van den Brink W, den Heeten G J, Booij J (2005) Validation of [123I] •-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology30: 996–1005
78.
de Win M M, de Jeu R A, de Bruin K, Habraken J B, Reneman L, Booij J, den Heeten G J (2004) Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol14: 185–189
79.
de Win M M L, Jager G, Vervaeke H, Schilt T, Reneman L, Booij J, Verhulst F C, den Heeten G J, Ramsey N F, Korf D J, van der Brink W (in press) The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int J Methods in Psychiatric Research
80.
Zhou F C, Tao-Cheng J H, Segv L, Patel T, Wang Y (1998) Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res805: 241–254
